BOKEH STOCK / Shutterstock.com
The global pandemic has increased collaboration and a new wave of disputes is likely. Arbitration is well placed to help, argue Kate Davies McGill, Gaela Gehring Flores and Paul Keller of Allen & Overy
The COVID-19 global pandemic has seen alliances between pharmaceuticals giants and, on the one hand, universities (Oxford University and AstraZeneca) and, on the other, small, family-owned biotechnology companies (BioNTech and Pfizer) to develop vaccines.
We have also seen institutions, governmental agencies, foundations and global vaccine alliances join forces with industry to manufacture and deliver the vaccines at a pace never seen before.
Partnership and collaboration is not new to the life sciences sector, however. They are established tools for sharing the know-how, skills and resources needed to conduct clinical trials, and then commercialise, market and distribute a product into the markets where it is most needed.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
arbitration, patent disputes, life sciences, covid-19, AstraZeneca, pfizer, Biontech, vaccines, medtech